Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years’ Experience at Pfizer

Rhea-AI Summary

Enochian BioSciences (NASDAQ: ENOB) announced the appointment of Greg Duczynski as Senior Vice President for Clinical Operations. Duczynski brings over 32 years of experience from Pfizer, where he held various leadership roles in Clinical Development and Operations. His expertise includes managing international gene therapy trials. CEO Dr. Mark Dybul emphasized Duczynski's significant background as a valuable addition as Enochian prepares to initiate several clinical studies. Duczynski expressed enthusiasm about Enochian's potential for growth with its innovative technologies and promising pipelines.

Positive

• Appointment of Greg Duczynski may enhance clinical operations leadership.
• Duczynski's extensive experience in clinical trials could accelerate product development.
• Potential to initiate several clinical studies in the near to medium term.

Negative

• None.

LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, announced today that Greg Duczynski is joining as Senior Vice President for Clinical Operations after a distinguished 32-year career with Pfizer. Since 2016, he has served as Senior Director, Clinical Development and Operations and Clinical Study Team Leader. He has been leading an international trial of gene therapy.

During his time at Pfizer, Greg took on increasing levels of leadership across a broad range of functions within the Clinical Operations space including Clinical Project Management, Study Management, Project Planning, Statistical Programming and Data Management.

“Greg’s extensive experience and outstanding leadership in clinical trials and advancing products to commercialization at the second largest pharmaceutical company in the world for more than three decades is an important and timely addition to Enochian BioSciences, as we prepare for the potential to begin several clinical studies in the near to medium term,” said Dr. Mark Dybul, the CEO of Enochian.

“I was very impressed by the science, project management and planning for clinical trials and commercialization of Enochian BioSciences,” Greg said. “It was not easy to leave a global powerhouse, but the potential for Enochian to grow with its two platform technologies and several promising pipelines for each is very compelling. I am very excited to be joining the team.”

FAQ

Who is Greg Duczynski and what is his role at Enochian BioSciences?

Greg Duczynski is the newly appointed Senior Vice President for Clinical Operations at Enochian BioSciences, bringing over 32 years of experience from Pfizer.

What experience does Greg Duczynski have in clinical operations?

Duczynski has extensive experience in Clinical Development and Operations, having led international trials and held various leadership roles at Pfizer.

What impact could Greg Duczynski's appointment have on Enochian BioSciences?

Duczynski's leadership and expertise may enhance Enochian's clinical operations and expedite the development of its promising therapies.

When does Enochian BioSciences plan to begin new clinical studies?

Enochian BioSciences is preparing to initiate several clinical studies in the near to medium term.